Pow-Sang J, Zaharia M, Ramirez G, Garcia J, Benavente V, Gonzales J
Prog Clin Biol Res. 1984;162B:33-7.
Eighteen patients with T1 transitional cell carcinoma of the urinary bladder were submitted to transurethral resection of the tumor, followed by Cobalt therapy (5,500 rads to the pelvis and 6,500 rads to the bladder in six weeks). The recurrence rate at three years follow-up was 33% (6/18). Recurrence of transitional cell carcinoma of the urinary bladder is a well known condition in stage O and A, even when low grade is present. Recurrence rates at one year as high as 84% (Loening et al., 1983) are reported in the current literature. In recent years many studies have been performed which were oriented to the use of intravesical chemotherapy in order to reduce the recurrence rate (Adolphs and Bastian, 1983; Huland, 1983; Loening et al., 1983; National Bladder Cancer Collaborative Group A, 1977; Rodriguez and Caserta, 1983; Zincke et al., 1983) of this tumor. We started a protocol on treatment of the transitional cell carcinoma of the urinary bladder in 1963. The protocol calls for transurethral resection of the tumor followed by Cobalt therapy. This is an interim report on stage T1 (stage A) with such a treatment.
18例膀胱T1期移行细胞癌患者接受了经尿道肿瘤切除术，随后进行钴治疗（六周内盆腔照射5500拉德，膀胱照射6500拉德）。三年随访时的复发率为33%（6/18）。膀胱移行细胞癌在O期和A期复发是一种众所周知的情况，即使存在低级别肿瘤。当前文献报道一年复发率高达84%（勒宁等人，1983年）。近年来，为了降低这种肿瘤的复发率（阿道夫斯和巴斯蒂安，1983年；胡兰，1983年；勒宁等人，1983年；国家膀胱癌协作组A，1977年；罗德里格斯和卡塞塔，1983年；津克等人，1983年），已经开展了许多关于膀胱内化疗应用的研究。我们于1963年启动了一项膀胱移行细胞癌治疗方案。该方案要求先进行经尿道肿瘤切除术，随后进行钴治疗。这是关于采用这种治疗方法的T1期（A期）的中期报告。
